ULVI BAYRAKTUTAN*
BIOCELL, Vol.46, No.7, pp. 1593-1598, 2022, DOI:10.32604/biocell.2022.018679
Abstract Ischaemic stroke is a debilitating disease with immense personal, societal and economic impact. Thrombolysis
with recombinant tissue plasminogen activator remains the only approved pharmacotherapy for this disease. As each year
less than 1% of eligible patients receive this therapy worldwide, efficacious new therapeutics are desperately needed.
Emerging evidence suggest endothelial progenitor cells (EPCs), capable of repairing damaged vasculature, as one such
therapeutics. However, questions regarding their optimal dose, delivery route and in vivo survivability remain largely
unanswered. Outgrowth endothelial cells, generated in large numbers by ex vivo expansion of EPCs, enable effective
assessment of these issues and may eventually serve… More >
Login
Register
